133 related articles for article (PubMed ID: 35633546)
21. Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF).
Ayala R; Martínez-López J; Gilsanz F
Cancer Cell Int; 2012 Jun; 12(1):25. PubMed ID: 22676581
[TBL] [Abstract][Full Text] [Related]
22. [Clinical features and prognostic factors in adult acute myeloid leukemia patients with FLT3-ITD and CEBPA gene co-mutation].
Pei RR; Zhang RH; Yu JF; Jiang ZX; Sun H; Wan DM; Xie XS; Liu YF; Li T; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):297-301. PubMed ID: 32447933
[No Abstract] [Full Text] [Related]
23. Chemotherapeutic Resistance in Egyptian Acute Myeloid Leukemia Patients.
Kassem NM; Medhat N; Kassem HA; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2421-2427. PubMed ID: 31450916
[TBL] [Abstract][Full Text] [Related]
24. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia.
Kuzmanovic M; Tosic N; Colovic N; Karan-Djurasevic T; Spasovski V; Radmilovic M; Nikcevic G; Suvajdzic-Vukovic N; Tomin D; Vidovic A; Virijevic M; Pavlovic S; Colovic M
Acta Haematol; 2012; 128(4):203-12. PubMed ID: 22906848
[TBL] [Abstract][Full Text] [Related]
26. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.
Wang L; Xu WL; Meng HT; Qian WB; Mai WY; Tong HY; Mao LP; Tong Y; Qian JJ; Lou YJ; Chen ZM; Wang YG; Jin J
J Zhejiang Univ Sci B; 2010 Oct; 11(10):762-70. PubMed ID: 20872983
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
[TBL] [Abstract][Full Text] [Related]
28. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.
Heidrich K; Thiede C; Schäfer-Eckart K; Schmitz N; Aulitzky WE; Krämer A; Rösler W; Hänel M; Einsele H; Baldus CD; Trappe RU; Stölzel F; Middeke JM; Röllig C; Taube F; Kramer M; Serve H; Berdel WE; Ehninger G; Bornhäuser M; Schetelig J;
Ann Oncol; 2017 Nov; 28(11):2793-2798. PubMed ID: 28945881
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
Elrhman HAEA; El-Meligui YM; Elalawi SM
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
[TBL] [Abstract][Full Text] [Related]
32. Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.
Kurosawa S; Yamaguchi H; Yamaguchi T; Fukunaga K; Yui S; Wakita S; Kanamori H; Usuki K; Uoshima N; Yanada M; Shono K; Ueki T; Mizuno I; Yano S; Takeuchi J; Kanda J; Okamura H; Inamoto Y; Inokuchi K; Fukuda T
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1125-1132. PubMed ID: 27040395
[TBL] [Abstract][Full Text] [Related]
33. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
[TBL] [Abstract][Full Text] [Related]
34. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
Schnittger S; Schoch C; Kern W; Mecucci C; Tschulik C; Martelli MF; Haferlach T; Hiddemann W; Falini B
Blood; 2005 Dec; 106(12):3733-9. PubMed ID: 16076867
[TBL] [Abstract][Full Text] [Related]
35. Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute Myeloid Leukemia.
Somerville TD; Wiseman DH; Spencer GJ; Huang X; Lynch JT; Leong HS; Williams EL; Cheesman E; Somervaille TC
Cancer Cell; 2015 Sep; 28(3):329-42. PubMed ID: 26373280
[TBL] [Abstract][Full Text] [Related]
36. The Clinicopathological Impact of Granulocyte-Macrophage Colony-Stimulating Factor Gene Expression and Different Molecular Prognostic Biomarkers in Egyptian Acute Myeloid Leukemia Patients.
Nagdy B; Kassem HA; Abdel-Ghaffar AB; Seoudi DM; Kassem NM
Asian Pac J Cancer Prev; 2020 Jul; 21(7):1993-2001. PubMed ID: 32711425
[TBL] [Abstract][Full Text] [Related]
37. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e469-e479. PubMed ID: 30082223
[TBL] [Abstract][Full Text] [Related]
38. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
[TBL] [Abstract][Full Text] [Related]
39. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
40. Novel mutations of the nucleophosmin (NPM-1) gene in Egyptian patients with acute myeloid leukemia: a pilot study.
Kassem N; Hamid AA; Attia T; Baathallah S; Mahmoud S; Moemen E; Safwat E; Khalaf M; Shaker O
J Egypt Natl Canc Inst; 2011 Jun; 23(2):73-8. PubMed ID: 22099964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
